uniQure (QURE) Misses Q1 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
uniQure Announces Financial Results for First Quarter 2015
June 11, 2015 5:52 AM EDTAMSTERDAM, The Netherlands, June 11, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced financial results for the first quarter ending March 31, 2015, and provided an update on multiple gene therapy programs.
Pipeline Updates
Hemophilia B: The Company has commenced screening patients in its first clinical trial site in Germany for its Phase I/II study of AMT-060 in hemophilia B patients and anticipates providing a preliminary readout of safety and efficacy data in the second half of 2015. Â Sanfilippo... More